Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)

About Bellerophon Therapeutics

Bellerophon Therapeutics logoBellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLPH
  • CUSIP:
Key Metrics:
  • Previous Close: $1.40
  • 50 Day Moving Average: $0.780
  • 200 Day Moving Average: $1.047
  • 52-Week Range: $0.43 - $4.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.32
  • P/E Growth: 0.000
  • Market Cap: $18.84M
  • Outstanding Shares: 14,506,000
  • Beta: -2.64
Profitability:
  • Return on Equity: -117.99%
  • Return on Assets: -91.74%
Debt:
  • Current Ratio: 3.67%
  • Quick Ratio: 3.67%
Additional Links:
Companies Related to Bellerophon Therapeutics:

Analyst Ratings

Consensus Ratings for Bellerophon Therapeutics (NASDAQ:BLPH) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.25 (617.05% upside)

Analysts' Ratings History for Bellerophon Therapeutics (NASDAQ:BLPH)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017HC WainwrightReiterated RatingBuy$5.00View Rating Details
8/11/2016Cowen and CompanyReiterated RatingBuyView Rating Details
3/22/2016FBR & CoReiterated RatingOutperform$11.00View Rating Details
3/22/2016Leerink SwannLower Price TargetOutperform$11.00 -> $9.00View Rating Details
3/16/2015SunTrust Banks, Inc.Initiated CoverageBuy$23.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/20/2017        
8/9/2016Q216($0.51)($0.39)ViewN/AView Earnings Details
5/10/2016Q116($0.65)($0.54)ViewN/AView Earnings Details
3/21/2016Q4($1.06)($0.82)ViewListenView Earnings Details
11/12/2015Q315($0.94)($0.86)ViewN/AView Earnings Details
4/1/2015($2.16)($1.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)
Current Year EPS Consensus Estimate: $-1.44 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.83)($0.42)($0.61)
Q2 20163($0.61)($0.46)($0.53)
Q3 20163($0.43)($0.35)($0.38)
Q4 20163($0.45)($0.28)($0.35)
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bellerophon Therapeutics (NASDAQ:BLPH)
Insider Ownership Percentage: 54.20%
Institutional Ownership Percentage: 44.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Jens LuehringDirectorBuy20,000$0.56$11,200.00View SEC Filing  
5/17/2016Jonathan M PeacockCEOBuy5,000$1.37$6,850.00View SEC Filing  
12/16/2015Jonathan M. PeacockCEOBuy20,300$2.75$55,825.00View SEC Filing  
8/19/2015Jonathan M PeacockCEOBuy5,000$5.48$27,400.00View SEC Filing  
5/20/2015Jonathan M PeacockCEOBuy5,560$8.69$48,316.40View SEC Filing  
2/19/2015Daniel TasseDirectorBuy25,000$12.00$300,000.00View SEC Filing  
2/19/2015Jonathan M PeacockCEOBuy20,800$12.00$249,600.00View SEC Filing  
2/19/2015Linde North America, Inc.Major ShareholderBuy358,916$12.00$4,306,992.00View SEC Filing  
2/19/2015Manesh NaiduInsiderBuy1,500$12.00$18,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bellerophon Therapeutics (NASDAQ:BLPH)
DateHeadline
News IconShares Ticking Lower in Trade: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - February 27 at 3:22 PM
News IconCompany Shares of Bellerophon Therapeutics, Inc. (BLPH) Rally ... - Highland Mirror (NASDAQ:BLPH)
www.highlandmirror.com - February 27 at 3:22 PM
News IconBellerophon Therapeutics, Inc. (NASDAQ:BLPH) (NASDAQ:BLPH)
interiordesignfuture.com - February 25 at 3:48 PM
News IconEquity in Review: Bellerophon Therapeutics Inc (BLPH) - The Standard (NASDAQ:BLPH)
6milestandard.com - February 24 at 8:55 PM
News IconHalo Games Will Bring Back Split-Screen, 343 Boss Says (NASDAQ:BLPH)
ekosvoice.com - February 24 at 12:57 PM
News IconThe Bellerophon Therapeutics, Inc. (BLPH) Given Buy Rating at HC Wainwright (NASDAQ:BLPH)
brassale.net - February 24 at 12:57 PM
News IconShares in Liberty Global PLC (LBTYA) Acquired by Seven Eight Capital LP (NASDAQ:BLPH)
prensariotiretail.com - February 23 at 3:55 PM
4-traders.com logoBellerophon Therapeutics LLC : LifeSci Capital Initiates Coverage of Bellerophon Therapeutics (NASDAQ:BLPH)
www.4-traders.com - February 23 at 3:55 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Bellerophon Therapeutics (NASDAQ:BLPH)
finance.yahoo.com - February 23 at 3:55 PM
News IconBellerophon Therapeutics, Inc. (NASDAQ:BLPH) has Current Market Capitalizaion of $39.87 Million (NASDAQ:BLPH)
www.graffiotech.com - February 22 at 9:04 PM
News IconVolatility Spiking as Shares Ride the Wave: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - February 22 at 4:01 PM
News IconIs a Pullback Coming For Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)? - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - February 22 at 4:01 PM
News IconStock Price of Bellerophon Therapeutics, Inc. (BLPH) Increases 52.11% - Money Flow Index & Trends (NASDAQ:BLPH)
www.moneyflowtrends.com - February 22 at 4:01 PM
News IconBellerophon Therapeutics Inc (NASDAQ:BLPH): What's Behind The Run? - Insider Financial (NASDAQ:BLPH)
www.insiderfinancial.com - February 22 at 4:01 PM
benzinga.com logo18 Biggest Mid-Day Gainers For Tuesday - Benzinga (NASDAQ:BLPH)
www.benzinga.com - February 21 at 3:16 PM
News IconAnalysts Peer Into Their Crystal Balls For Bellerophon Therapeutics Inc (NASDAQ:BLPH): Where Is It headed? - Winfield Review (NASDAQ:BLPH)
winfieldreview.com - February 21 at 9:33 AM
News IconAnalyst Views On Top Movers In Recent Trade: Bellerophon Therapeutics, Inc. (BLPH), PharmAthene, Inc. (PIP) - Post Analyst (NASDAQ:BLPH)
postanalyst.com - February 21 at 9:33 AM
News IconBellerophon Therapeutics, Inc. (BLPH): Thoughts on the Momentum - Post Analyst (NASDAQ:BLPH)
postanalyst.com - February 20 at 11:10 AM
istreetwire.com logoStocks on the Move: Cobalt International Energy, Inc. (CIE), Bellerophon Therapeutics, Inc. (BLPH), Sino-Global ... - iStreetWire (NASDAQ:BLPH)
istreetwire.com - February 16 at 5:42 AM
News IconImpact of Brokerage Rating on Bellerophon Therapeutics, Inc.(BLPH) - Highland Mirror (NASDAQ:BLPH)
www.highlandmirror.com - February 16 at 5:42 AM
News IconPrice Target Analysis: RXi Pharmaceuticals Corporation (NASDAQ:RXII) (NASDAQ:BLPH)
xboxonezone.com - February 13 at 4:28 PM
News IconAnalyst Research Consensus on Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Rives Journal (NASDAQ:BLPH)
rivesjournal.com - February 10 at 3:26 PM
News IconBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Dipping Lower Ahead of the Market Open - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - February 10 at 3:26 PM
News IconA Look at this Riveting Stock: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 31 at 9:14 PM
News IconCheap Stock, But is it a Bargain: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 31 at 9:14 PM
News IconBargain Hunters Should Take a Look at Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 31 at 1:50 AM
News IconSell-side is Weighing in on Bellerophon Therapeutics Inc (NASDAQ:BLPH) Earnings & Targets - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - January 31 at 1:50 AM
News IconBellerophon Therapeutics Inc BLPH Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BLPH)
www.bioportfolio.com - January 27 at 2:39 AM
News IconEarnings in Full Force, Analysts Take Aim at Bellerophon Therapeutics Inc (NASDAQ:BLPH) - Wall Street Beacon (NASDAQ:BLPH)
wsbeacon.com - January 25 at 4:33 PM
News IconThe Bellerophon Therapeutics Inc. (BLPH) Research Coverage Started at HC Wainwright (NASDAQ:BLPH)
flapship.com - January 24 at 4:28 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 23 at 8:32 PM
News IconAnalysts Take the Wheel on Bellerophon Therapeutics Inc (NASDAQ:BLPH) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - January 23 at 8:32 PM
News IconBellerophon Therapeutics, Inc. (BLPH) Broker Views On Wall Street - NewsDen (NASDAQ:BLPH)
newsden.net - January 21 at 8:55 PM
News IconYuvraj, Dhoni tons power India to 381-6 against England (NASDAQ:BLPH)
latribunadecanarias.com - January 21 at 3:04 AM
smarteranalyst.com logoFriday’s Market Insights: Interpace Diagnostics Group Inc (IDXG), Skyworks Solutions Inc (SWKS), and Bellerophon Therapeutics Inc (BLPH) (NASDAQ:BLPH)
www.smarteranalyst.com - January 21 at 3:04 AM
smarteranalyst.com logoHere's Why Bellerophon Therapeutics Inc (BLPH) Stock Rose 16% Today - Smarter Analyst (NASDAQ:BLPH)
www.smarteranalyst.com - January 20 at 5:01 PM
finance.yahoo.com logoCoverage initiated on Bellerophon Therapeutics by H.C. Wainwright (NASDAQ:BLPH)
finance.yahoo.com - January 20 at 5:01 PM
News IconKanye West wasn't asked to play Donald Trump's inauguration (NASDAQ:BLPH)
mjbstar.com - January 19 at 8:39 PM
News IconMark Zuckerberg 'sues families to force them to sell land' (NASDAQ:BLPH)
seputarkita.info - January 19 at 8:39 PM
News IconCrime survey reveals 12 million cyber offences took place in one year (NASDAQ:BLPH)
vouxmagazine.com - January 19 at 8:39 PM
News IconIs This Equity Ready for a Breakout: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) (NASDAQ:BLPH)
seputarkita.info - January 19 at 3:37 PM
News IconAnika Therapeutics Inc. (NASDAQ:ANIK) Reviewed By Analysts (NASDAQ:BLPH)
baddgoddess.com - January 19 at 3:37 PM
News IconBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Eps and Price target Analysis (NASDAQ:BLPH)
diariocatolico.net - January 19 at 3:37 PM
istreetwire.com logoStocks Buzz: salesforce.com, inc. (CRM), Vonage Holdings Corp. (VG), Bellerophon Therapeutics, Inc. (BLPH) - iStreetWire (NASDAQ:BLPH)
istreetwire.com - January 18 at 3:22 PM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 17 at 9:33 AM
News IconStock Update on Earnings & Estimates for Bellerophon Therapeutics Inc (NASDAQ:BLPH) - Aiken Advocate (NASDAQ:BLPH)
aikenadvocate.com - January 17 at 9:33 AM
News IconDelving into Shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 12 at 2:22 AM
News IconCalling all Bargain Hunters: Stock Update on Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 11 at 2:34 AM
News IconPlacing the Bulls-Eye Focus on Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) - Prospect Journal (NASDAQ:BLPH)
prospectjournal.com - January 11 at 2:34 AM
marketexclusive.com logoBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued ... - Market Exclusive (NASDAQ:BLPH)
marketexclusive.com - January 9 at 1:54 AM

Social

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2017?

4 analysts have issued 1-year price targets for Bellerophon Therapeutics' shares. Their forecasts range from $5.00 to $12.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $9.25 in the next year.

When will Bellerophon Therapeutics announce their earnings?

Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 20th 2017.

Who owns Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Boxer Capital LLC (12.80%), FMR LLC (8.33%), Armistice Capital LLC (6.89%) and Renaissance Technologies LLC (1.65%). Company insiders that own Bellerophon Therapeutics stock include Jens Luehring and Jonathan M Peacock.

Who bought Bellerophon Therapeutics stock? Who is buying Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Armistice Capital LLC and Renaissance Technologies LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Jens Luehring and Jonathan M Peacock.

How do I buy Bellerophon Therapeutics stock?

Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bellerophon Therapeutics stock cost?

One share of Bellerophon Therapeutics stock can currently be purchased for approximately $1.29.

Bellerophon Therapeutics (NASDAQ:BLPH) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Earnings History Chart

Earnings by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Dividend History Chart

Dividend Payments by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Last Updated on 2/27/2017 by MarketBeat.com Staff